Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615265 | 0.92 | ALDH1A1 (0.36) | ALDH1A1ROR1PTPN1 | |
| SCHEMBL31166793 | 0.82 | ALDH1A1 (0.35) | ALDH1A1ROR1PTPN1 | |
| SCHEMBL616025 | 0.77 | ROR1 (0.38) | ALDH1A1ROR1PTPN1 | |
| SCHEMBL6437802 | 0.76 | ALDH1A1 (0.36) | ALDH1A1ROR1PTPN1 | |
| SCHEMBL31167221 | 0.71 | FYN (0.34) | ALDH1A1ROR1 | |
| SCHEMBL6433538 | 0.68 | ROR1 (0.34) | ALDH1A1ROR1PTPN1 | |
| SCHEMBL31432509 | 0.68 | ALOX15 (0.40) | ALDH1A1ROR1 | |
| SCHEMBL616927 | 0.68 | HDAC3 (0.32) | ALDH1A1ROR1 | |
| SCHEMBL8751797 | 0.67 | HDAC8 (0.46) | ALDH1A1ROR1 | |
| SCHEMBL31166821 | 0.67 | PDE2A (0.40) | ROR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2529735-B1 | COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY | GALDERMA RES & DEV (FR) | 2014-06-25 | — | — | EP | disclosed |
| US-8372879-B2 | 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-12 | — | — | US | disclosed |
| EP-2529735-A1 | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | Galderma Research & Development (FR) | 2012-12-05 | — | — | EP | disclosed |
| EP-2373310-B1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | TYR, DDT, PAH | ALDH1A1 56/4885ROR1 341/4885PTPN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.